VAGISTAT-1
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VAGISTAT-1 (VAGISTAT-1).
Tioconazole is an imidazole antifungal that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and fungal growth.
| Metabolism | Minimal systemic absorption; metabolized in the liver if absorbed, but extensive first-pass metabolism limits systemic availability. |
| Excretion | Approximately 50% is excreted unchanged in feces via biliary elimination; less than 1% is excreted unchanged in urine. |
| Half-life | The terminal elimination half-life is approximately 5-7 days, reflecting prolonged vaginal retention and slow systemic absorption. |
| Protein binding | Approximately 80-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The apparent volume of distribution is approximately 0.5-0.7 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Systemic bioavailability after intravaginal administration is less than 5% due to limited absorption. |
| Onset of Action | Clinical effect (resolution of symptoms) typically begins within 24-48 hours after a single intravaginal application. |
| Duration of Action | Therapeutic concentrations persist for at least 3-7 days after a single dose, with clinical cure rates maintained for up to 7-10 days. |
One 300 mg vaginal suppository administered as a single dose.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients below 12 years have not been established. For adolescents 12 years and older, same as adult dosing: one 300 mg vaginal suppository as a single dose. |
| Geriatric use | No specific dosage adjustment recommended; same as adult dosing: one 300 mg vaginal suppository as a single dose. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VAGISTAT-1 (VAGISTAT-1).
| Breastfeeding | It is not known whether tioconazole is excreted in human milk following intravaginal administration. Due to low systemic absorption (approximately 0.89% of dose), excretion is likely minimal. M/P ratio is unknown. Caution is advised; consider benefits of breastfeeding and mother's need for drug. |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, intravaginal administration of tioconazole (600 mg single dose) during organogenesis produced no teratogenic effects at systemic exposures similar to human exposure. However, embryotoxicity (increased resorptions) was observed at maternally toxic doses. Risk cannot be ruled out; use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to tioconazole or any component of the formulation.
| Precautions | For intravaginal use only. Discontinue if irritation or hypersensitivity occurs. Not for use in children under 12 years unless directed by physician. Avoid use during menstruation. May reduce efficacy of latex condoms and diaphragms. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine pregnancy monitoring. Monitor for signs of maternal adverse effects (e.g., vaginal irritation, burning). Fetal monitoring not indicated due to low systemic absorption. |
| Fertility Effects | No studies on fertility in humans. Animal studies (rats) with intravaginal tioconazole showed no impairment of fertility at doses up to 200 mg/kg/day. No known effect on human fertility. |